
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
References for: Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
over 8 years ago
Medical World News: Clinical/Managed Care Updatesover 8 years ago
Medical World News: Clinical Updatesover 8 years ago
Medical World News: Regulatory Updates





